Feature|Podcasts|October 25, 2024

Fake Weight Loss Drugs: Growing Threat to Consumer Health

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss:

  • Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks
  • What can be done to raise awareness among consumers about the dangers of counterfeit medications
  • Ways increase access to legitimate weight loss medications, especially for those in underserved communities
  • and much more!

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.